you and everyone. during of hope Good you morning, these Thanks, well and And this unprecedented challenging Particularly Will. joining I your safe. and times, thank us today. all families finds for
Despite COVID-XX in trial we that achieve the employees possible on safety clinical am our safeguard have that we and clinical the our I of times, this every to taken of pandemic, impact at Bio-Path, milestones report health here and to these and to pleased difficult participants, even social extensive remain precaution track year.
inflection a The throughout important continues XXXX. us in for foundation as advance considerable to made clinical serve we toward points progress to our pipeline XXXX
threatening As DNAbilize RNAi to with platform continuing of a suffering it nanoparticle programs, cancer advance now, stands treat we on indications. our are life built to innovative patients our variety
key of our features. a with platform DNAbilize begin review and me its Let
nucleic use creation is platform nanoparticle antisense RNAi you technology, of which the for we As therapeutics. proprietary know, our the acid DNAbilize
cell drug our associated with integrate the to be technology. delivered high incorporation antisense There's been of disease to structure, DNAbilize toxicity into with of evidence the no uptake layers. membrane cells unique into with via lipid the the because allowing their therapeutics cellular
with medical We are novel of unmet high for potential platform extremely from patients for our enthusiastic DNAbilize need. about the developing diseases treatments suffering
product have treatment where a is we turn let's AML. clinical substantial the for being to in our lead months. Now, progress candidate, Prexigebersen trial studied of in Phase recent prexigebersen, II made
a this studied originally is prexigebersen trial regimens As patients with a who LDAC otherwise novo multicenter low regimen. cytarabine eligible a chemotherapy previously or for high de trial or reminder, untreated in that standard were or low-dose combination with not intensity had who intensity elected AML
open two-stage efficacy the to The label, pharmacodynamics trial a and of prexigebersen. design with assess was profile, pharmacokinetics, safety
that hematologic study patients was complete remission, complete achieve with The of platelet who primary incomplete remission including endpoint incomplete recovery recovery. and
tests. Secondary laboratory survival, of time safety duration clinical events and findings, as of evaluated vital efficacy examination and signs overall including and the prexigebersen, response adverse endpoints physical response, to by assess
AML interim from underscored As increased of you II may one prexigebersen and efficacy prexigebersen and presented we of only recall, compelling safety confidence study patients study. treat this last Phase our These results potential profile patients. results in updated interim year, novo its AML the stage to de in our of from
in were encouraged standard data of advancement and care. These of to compelling prexigebersen combination particularly the prioritize us with
therapy. de ideal The combination prexigebersen view add of for with to combination provided venetoclax approval therapy, of We the treatment the as an plus an frontline prexigebersen the to venetoclax, of decitabine AML opportunity candidate novo frontline patients.
is to improve aim prexigebersen patients. options frontline leading for to therapies the add treatment Our to
prexigebersen development program will treatment registration for directed to landscape the as for to respond for advances. As evolves, continue AML reflects clinical changes. treatment a plans The these those our we
the of with dose evaluated prexigebersen for of be I The evaluable safety decitabine determined milligram evaluated a safe patients study combination prexigebersen The patients safety amended Phase a cohorts at and meter. per in patients. II to of study XX assessment combination the of square and six both decitabine in
We the next and to add combination both cohorts of test venetoclax treatment modifying patients to are testing in triple prexigebersen/decitabine combination. of process safety the of for the
Once combination, efficacy anticipated trial It include combination this of with whether six that of prexigebersen/decitabine/venetoclax standard significance. of each of care cohort the completed efficacy safety can exceeds the XX patients statistical commence. we that the segment interim assessment therapy prexigebersen/decitabine/venetoclax the current treatment have of will the evaluable of would an of assess assessment is patient the efficacy
States, Drug Upon United such now the expected approval. sites X favorable is the the clinical program. intend II we efficacy The which have segment at the accelerated sites Administration, the data, for and petition US XX in FDA, trial to we to Phase to of Food of conducted be committed
our turning to of on planned Before trial cancer. solid Phase patients tumors, with ovarian, programs, and breast touch uterine, prexigebersen-A briefly like I hormone pancreatic clinical I'd in including to refractory our advanced other
is drug for drug modified properties. Prexigebersen-A, the candidate, a product substance a nanoparticle fourth Bio-Path prexigebersen with enhanced sharing same
conducted be often poor evaluate centers provide cancer and for benefit such in to cancer may with several is safety have prexigebersen-A at initially planned This Patients of tumor solid And clinical our it patients. is ovarian prexigebersen-A the trial that expected endometrial and leading patients. to outcomes. diagnosed is recurrent hope
We application, and begin filed an this to new study drug or in IND, expect investigational XXXX.
Venetoclax domain. the we targets for activity our has BHX year, plans which our BPXXXX. for to protein's shown therapeutic second neutralizing Turning BPXXXX, works antiapoptotic by pipeline Bcl-X. candidate, an Bcl-X, second the filed against also application Last now protein, IND candidate, and
an or for CLL, chronic patients lymphocytic It patients. leukemia, untreated and treatment AML is improved
patients the mutation with cell oftentimes with occurs disease of BHX However, time. domain's exception treated relapse to invariably stem some transplantation, over due
the targets also Bcl-X BPXXXX protein.
and is RNA, activity the based Bcl-X messenger BHX the domain. BPXXXX not on However, blocking
provide BPXXXX venetoclax have relapsed, received could patients AML we who patients a previously As alternative who including believe an for that result, treatments. venetoclax
BPXXXX CLL, a including to In clearance AML occur. lymphoma. November include those relapses amend IND can venetoclax XXXX, We this for us FDA the granted to study relapses treatment potential if and as registration
Bcl-X us venetoclax include in to driven give in combination The II antiapoptosis AML treatments these planned patients. treating prexigebersen clinical Phase with will our with modification experience of program early
expect in first begin study in the human summer our XXXX. of BPXXXX of We to
or recently, for this the planned study Most Annual we Cancer Phase advanced with our highlighting patients poster BPXXXX first-in-human of design lymphoid AACR, Research, Meeting, Association a trial the April, of malignancies. I presented at clinical in American
Phase leading I Cancer the the and is cancer centers, trial The be MD at Center Georgia to conducted Canon of including Institute. Cancer Research clinical the several Texas University expected Anderson Center, Sarah
STATX me let are future and has progress preclinical the of Finally, very This review third this we program excited promising BPXXXX, for targets our data program. our candidate, drug with which shown protein. the
drug enhance standard the of pancreatic penetrate Previous frontline successfully and efficacy model. are BPXXXX a cancer treatment tumor models tumors treatments. patient-derived pancreatic of in We for studying shown the the have to
are though for inactive a active program of cell STATX in aberrantly reasons. resists Signal cancer distant regulator induce or processes. in and these cells, is organs genes of tumor number potential cells The Transduction cancer. uncontrollably normal formation is to STATX The vascular recognized our is a Activator cancer or death, cells. abilities proliferate compelling invade STATX, well and Transcription-X, in for hallmarks apoptosis, of of the typically of involved
and to cancer destruction More the evade recently, the research significant has of in by gained system capability field. immune the human avoid immune system acceptance also tumors surveillance
many tumor evasion for STATX, oncogenic which of of multiple immune convergence at a critical a levels. point mediator emerged pathways, is as has
clinical has expected lung disease linked considered STATX with correlates Activation cancer, grade chemotherapy, of AML, and been non-small standard has many pancreatic agent found types metastasis, benefit. STATX outcome, to chemotherapy Activation for and of of in been and in high cancer. poor to enhanced inhibition clinical cancers, pancreatic cell with care advanced STATX gemcitabine, including produce of is of a Therefore, resistance with cancer. combination including
antisense four STATX highlighted nanoparticle against program messenger Bio-Path this using and oligo for antisense data RNA manufactured sequences identified preclinical by RNA Our directed DNAbilize technology.
with liposome inhibitory STATX cell determine antisense cells. were lung pancreatic oligo of patient-derived with xenografts on live conducted panel BPXXXX a XX to tissue the of and An viability sensitivity of ex Cell and Western incorporated overall alone in gemcitabine. and effects tests cancer was study blots assay activity vivo AML combination to the non-small performed
viability greater X.XX defined value a with than previously than as a inhibition slice response. criteria, Using counted of p less tissue XX%
derived for of days. to days. cancer vivo pancreatic BPXXXX tumor ex for mice monitored results, week volumes a twice up bearing For XX validation XX gemcitabine administered were patient of Tumor were and xenografts
of of a live slice than cancer micro the with a XX% viability assay, p pancreatic out X.XX. at than by In the moles XX tissue in inhibited less X value XX significantly dose point BPXXXX patient more tissue derived xenografts
when cancer had BPXXXX patient-derived combination was The the of xenograft combination caused of drug the pancreatic XX anti-cancer a vivo BPXXXX vivo of tumor and This period. gemcitabine In further in during in a models, enhanced and derived days maintained drug ceased. with regression another study XX-day treatment activity xenografts. gemcitabine treatment for BPXXXX of patient even ex efficacy subset
validation cell and protein BPXXXX potent liposome most cell addition, selected demonstrated sequence AML in BPXXXX decreasing that cells cancer STATX STATX was the Further non-small viability cell lung in as In incorporated antisense viability. expression. inhibited
encouraging by These very were the data well scientific community. received
We are challenging cutting-edge our to an has this indication of particularly especially first-in-human therapy cancer excited in treatment validation limited options. launch that
file promising study this in year, an very application Moving IND-enabling IND are the for undertaking this goal a we BPXXXX an forward, with year. to later product with candidate
driving pandemic, forward global during can to development remained this we challenging As time. despite committed our see, you clinical have COVID-XX programs
in capitalize remain technology new advance various and our continue platform potential to the to evaluating We our indications. of on to opportunities programs important committed DNAbilize oncology
of our over program now first to sheet XXXX with financials Anthony I'll review Price balance for that, quarter With Anthony? brief the highlights. a turn along
